US OptionsDetailed Quotes
ATRC250117C20000
- 10.41
- 0.000.00%
15min DelayClose Jan 3 15:59 ET
0.00High0.00Low
10.41Open10.41Pre Close0 Volume8 Open Interest20.00Strike Price0.00Turnover0.00%IV-5.06%PremiumJan 17, 2025Expiry Date12.03Intrinsic Value100Multiplier14DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.71Leverage Ratio--Theta--Rho--Eff Leverage--Vega
AtriCure Stock Discussion
Sign in to post a comment
$Garmin (GRMN.US)$ $AtriCure (ATRC.US)$ $Vast Renewables (VSTE.US)$ $ASP Isotopes (ASPI.US)$ $Unisys (UIS.US)$ $Solidion Technology (STI.US)$ $NerdWallet (NRDS.US)$ $Xilio Therapeutics (XLO.US)$ $Cryo-Cell International (CCEL.US)$ $Omnicell (OMCL.US)$ $Reddit (RDDT.US)$ $Ensysce Biosciences (ENSC.US)$ $Tharimmune (THAR.US)$
5
1
1
$SeaStar Medical (ICU.US)$ $Direxion Daily GOOGL Bull 2X Shares (GGLL.US)$ $Torrid (CURV.US)$ $Snap Inc (SNAP.US)$ $60 Degrees Pharmaceuticals (SXTP.US)$ $GlycoMimetics (GLYC.US)$ $Mirion (MIR.US)$ $AtriCure (ATRC.US)$ $Reddit (RDDT.US)$ $Magic Empire Global (MEGL.US)$ $Sky Quarry (SKYQ.US)$ $Enovix (ENVX.US)$ $NerdWallet (NRDS.US)$ $Starbox Group (STBX.US)$
📊⚡️📊
📊⚡️📊
4
Insider transactions at AtriCure are not encouraging. However, insiders' share ownership suggests some alignment. Maggie Yuen's sale at a price above the current share price may not reflect insider confidence.
Investors forecast sustained strong revenue performance from AtriCure, reflected in a high P/S ratio. Shareholders currently show confidence in the company's future revenue, bolstering its shares. The high P/S ratio is deemed appropriate due to robust future revenues.
The lack of insider purchasing and ample selling in the past year could be red flags for potential investors in AtriCure. Despite high insider ownership, absence of buying is unsettling. Additionally, unspecified risks and concerns for AtriCure are noteworthy.
No comment yet
Den the Dragon :
